BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 86 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q1 2022. The put-call ratio across all filers is 15.47 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $63,286 | -23.0% | 22,051 | +35.5% | 0.00% | – |
| Q2 2023 | $82,158 | +55.4% | 16,269 | -41.8% | 0.00% | – |
| Q1 2023 | $52,871 | -5.9% | 27,974 | -10.3% | 0.00% | – |
| Q4 2022 | $56,164 | -85.5% | 31,202 | -86.4% | 0.00% | – |
| Q3 2022 | $387,000 | -70.7% | 229,189 | -57.3% | 0.00% | – |
| Q2 2022 | $1,319,000 | -3.4% | 536,220 | +8.7% | 0.00% | – |
| Q1 2022 | $1,366,000 | -66.9% | 493,362 | -36.3% | 0.00% | -100.0% |
| Q4 2021 | $4,127,000 | -35.9% | 773,936 | +1.7% | 0.00% | 0.0% |
| Q3 2021 | $6,439,000 | -12.1% | 761,091 | +26.6% | 0.00% | 0.0% |
| Q2 2021 | $7,327,000 | +2255.9% | 601,020 | +4599.9% | 0.00% | – |
| Q1 2021 | $311,000 | -91.3% | 12,788 | -88.5% | 0.00% | -100.0% |
| Q4 2020 | $3,578,000 | +1292.2% | 111,661 | +1212.0% | 0.00% | – |
| Q3 2020 | $257,000 | +59.6% | 8,511 | +123.0% | 0.00% | – |
| Q2 2020 | $161,000 | +360.0% | 3,816 | +170.6% | 0.00% | – |
| Q1 2020 | $35,000 | – | 1,410 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 3,449,845 | $5,830,000 | 0.29% |
| K2 PRINCIPAL FUND, L.P. | 1,031,511 | $1,743,000 | 0.20% |
| Boxer Capital, LLC | 2,014,858 | $3,405,000 | 0.19% |
| DAFNA Capital Management LLC | 313,600 | $530,000 | 0.14% |
| Newtyn Management, LLC | 350,000 | $592,000 | 0.13% |
| Artal Group S.A. | 1,646,517 | $2,783,000 | 0.12% |
| Bellevue Group AG | 4,717,113 | $7,972,000 | 0.11% |
| MPM BioImpact LLC | 239,888 | $405,000 | 0.10% |
| RA Capital Management | 2,589,904 | $4,377,000 | 0.09% |
| Beacon Capital Management, LLC | 35,615 | $88,000 | 0.03% |